Gastric cancer with peritoneal metastases has a dismal prognosis. Cytoreductive surgery (CRS) is effective, but the impact of hyperthermic intraperitoneal chemotherapy (HIPEC) remains controversial. A French multicentric study compared the effect of adding HIPEC to surgery alone in 277 patients. The study, which was published in one of the best cancer journals, shows that additional HIPEC improved survival without additional complications or death cases. However, results of this study can only be applied to strictly selected patients with limited extent of peritoneal metastasis.
- Covid-19 pandemia: ISSPP recommendation for the therapy of patients with peritoneal and pleural metastasis
- Preannouncement: 2nd ISSPP congress to be held in Rome, Italy, from Oct 14 to 15th, 2021.
- Phase III EXPEL Trial Finds No Survival Gain From Extensive Intraoperative Peritoneal Lavage in Gastric Cancer
- First PIPAC in the United States of America, Mayo Clinic
- Peritoneum Prize 2019 awarded to Willemien J van Driel, MD PhD